Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124552 | 0.89 | KMT2A (0.49) | KMT2AMEN1SIGMAR1LMNAMAPT | |
| SCHEMBL5129058 | 0.86 | MEN1 (0.50) | KMT2AMEN1LMNAMAPTTSHR | |
| SCHEMBL5118130 | 0.78 | GRM5 (0.48) | KMT2AMEN1LMNATSHRGRM5 | |
| SCHEMBL5115621 | 0.77 | CYP1A2 (0.44) | KMT2AMEN1LMNAHTTGRM5 | |
| SCHEMBL5123094 | 0.77 | VHL (0.43) | MAPTGRM5 | |
| SCHEMBL5121798 | 0.76 | MEN1 (0.47) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL5129292 | 0.76 | KDM4E (0.51) | KMT2AMEN1MAPTGRM5ALDH1A1 | |
| SCHEMBL5119623 | 0.75 | TP53 (0.51) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5119545 | 0.75 | GRM5 (0.52) | KMT2AMEN1GRM5 | |
| SCHEMBL5128993 | 0.74 | HTR4 (0.47) | KMT2AMEN1TSHRGRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | KMT2A 1939/4885MEN1 4024/4885SIGMAR1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.